0001415889-24-015533.txt : 20240605
0001415889-24-015533.hdr.sgml : 20240605
20240605143739
ACCESSION NUMBER: 0001415889-24-015533
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240604
FILED AS OF DATE: 20240605
DATE AS OF CHANGE: 20240605
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hannah Brendan
CENTRAL INDEX KEY: 0001929422
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38890
FILM NUMBER: 241021677
MAIL ADDRESS:
STREET 1: 269 EAST GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Quince Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662774
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 901024039
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 611 GATEWAY BLVD., SUITE 273
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-910-5717
MAIL ADDRESS:
STREET 1: 611 GATEWAY BLVD., SUITE 273
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Cortexyme, Inc.
DATE OF NAME CHANGE: 20160104
4
1
form4-06052024_060635.xml
X0508
4
2024-06-04
0001662774
Quince Therapeutics, Inc.
QNCX
0001929422
Hannah Brendan
C/O QUINCE THERAPEUTICS, INC.
611 GATEWAY BLVD, SUITE 273
SOUTH SAN FRANCISCO
CA
94080
false
true
false
false
CHIEF BUSINESS OFFICER AND COO
0
Common Stock
2024-06-04
4
M
0
56061
0.55
A
257616
D
Employee Stock Option (right to buy)
0.55
2024-06-04
4
M
0
56061
0
D
2032-03-27
Common Stock
56061
47439
D
The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years.
/s/ Brendan Hannah
2024-06-05